Abstract
This chapter focuses on costing methods usually applied in cost analysis and health-related economic evaluations. The quality of an economic evaluation depends on the quality and precision of data collection and on transparency and comprehensivenness of costing resources. Costs, from an economic perspective, are related to opportunity costs; this economic conceptualization is different from a financial perspective. Costs are classified as direct, indirect, intangible, and total costs. In this chapter I focus exclusively on the measurement of direct costs. Costing involves multiple steps: choosing the perspective of the study; identifying the component of costs, collecting data on costs and services use, estimating the unit cost for each resource, and estimating costs. Although the majority of economic evaluations includes only direct costs, indirect costs correspond to the major parcel of diseases costs. Mental disorders, for instance, cause innumerable negative externalities and indirect costs, and the benefits of psychiatric and psychosocial interventions go beyond clinical improvement, leading to systematic recommendations for measuring costs in a comprehensive way, such as using societal perspective. There is a debate among health economists regarding the inclusion of indirect costs in the economic evaluation, though, thieir exclusion in assessing cost-effectivenness, for instance, might understimate the economic impact of psychiatric intervention. Costing methods for indirect costs are discussed in another chapter in this book.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reference
Mogyorosy Z, Smith P. The main methodological issues in costing health care services. Centre for Health Economics, University of York; 2005. 12 Feb 2016.
Barnett PG. Review of methods to determine VA health care costs. Med Care. 1999;37(4 Suppl Va):AS9–17.
Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care. 1990;6(1):57–75.
Garrison Jr LP, Mansley E, Abbott T, Bresnahan B, Hay J, Smeedin J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal Perpective the ISPOR drug costs task force report – part II. Value Health. 2010;13(1):8–13.
Drummond M, McGuire A. Economic evaluation in health care: merging theroy with practice. 2nd ed. New York: Oxford University Press; 2004.
Shearer J, McCrone P, Romeo R. Economic evaluation of mental health interventions: a guide to costing approaches. PharmacoEconomics. 2016;34(7):651–64.
Drummond MF, Sculpher MJ, Torrance GW, O` Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2007.
Smith MW, Barnett PG. Direct measurement of health care costs. Med Care Res Rev. 2003;60(3 Suppl):74S–91S.
Beecham J. Collecting and estimating costs. In: Knapp M, editor. The economic evaluation of mental health care. 1st ed. Aldershot: Arena; 1995. p. 61–82.
Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs. London: Gaskell; 2001. p. 200–24.
Byford S, McDaid D, Sefton T. Because it’s worth it: a practical guide to conducting economic evaluations in the social welfare field. 2003. London, York Publishing Services Ltd.
Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. 2nd ed. Oxford: Oxford University Press; 2004. p. 68–93.
Slothuus U. An evaluation of selected literature on the measurement of costs in health economic evaluations. Odense: Syddansk Universitets Trykkeri. Health Economics Papers, 3. 2000. http://www.sdu.dk/-/media/files/om_sdu/centre/cohere/working+papers/20005.pdf
Institute for Quality and Efficiency in Health Care (IQWiG). Working paper: cost estimation. Cologne; 2009.
Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. A review. Int J Technol Assess Health Care. 1998;14(4):799–808.
Barnett PG. An improved set of standards for finding cost for cost-effectiveness analysis. Med Care. 2009;47(7 Suppl 1):S82–8.
Heerey A, McGowan B, Ryan M, Barry M. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res. 2002;2(1):29–33.
Oostenbrink JB, oopmanschap MA, Rutten FF. Standardisation of costs: the Dutch manual for costing in economic evaluations. PharmacoEconomics. 2002;20(7):443–54.
Drummond M, Sculpher MJ. Common methodological flaws in economic evaluations. Med Care. 2005;43(suppl7):II5–II14.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.
Adam T, Evans D. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care. 2003;19(2):407–20.
Edwards RT, Charles JM, Lloyd-Williams H. Public health economics: a systematic review of guidance for the economic evaluation of public health interventions and discussion of key methodological issues. BMC Public Health. 2013;13:1001.
McCrone P. Mental health economics: current methodological issues. Epidemiol Psychiatr Sci. 2011;20(3):239–43.
McCrone P, Weich S. Mental health care costs: paucity of measurement. Soc Psychiatry Psychiatr Epidemiol. 1996;31(2):70–7.
Knapp M. The economic evaluation of mental health care. 1st ed. Ashgate Publishing Limited; 1995.
Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10:357–9.
Neumann PJ. Costing and perspective in published cost-effectiveness analysis. Med Care. 2009;47(7 Suppl 1):S28–32.
Hu TW. Perspectives: an international review of the national cost estimates of mental illness, 1990–2003. J Ment Health Policy Econ. 2006;9(1):3–13.
Unutzer J, Katon WJ, Russo J, Simon G, Von KM, Lin E, et al. Willingness to pay for depression treatment in primary care. Psychiatr Serv. 2003;54(3):340–5.
Xu K, Evans DB, Kawabata K, Zeramdini R, Murray C. Household catastrophic health expenditure: a multicountry analysis. Lancet. 2003;362:111–7.
Tai B, Bae Y, Le Q. A systematic review of health economic evaluation studies using the patient’s perspective. Value Health. 2016;19(6):903–8.
Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.
Knapp M, Beecham J. Reduced list costings: examination of an informed short cut in mental health research. Health Econ. 1993;2(4):313–22.
Knapp M, Razzouk D. Costs of schizophrenia. Psychatry. 2008;7(11):491–4.
Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10(1):23–41.
Cidav Z, Marcus SC, Mandell DS. Implications of childhood autism for parental employment and earnings. Pediatrics. 2012;129(4):617–23.
Barrett B, Byford S, Sharac J, udry K, Leadbitter K, emple K, et al. Service and wider societal costs of very young children with autism in the UK. J Autism Dev Disord. 2012;42:797–804.
Knapp M. Hidden costs of mental illness. Br J Psychiatry. 2003;183:477–8.
Miller T, Levy D, Cohen M, Cox KL. Costs of alcohol and drug-involved crime. Prev Sci. 2006;7(4):333–42.
Chisholm D, Evans D. Economic evaluation in health: saving money or improving care? J Med Econ. 2007;10:325–37.
Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079–87.
Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016;17(9):1245–9.
McDaid D, Knapp M, Medeiros H. MHEEN group. Employment and mental health: assessing the economic impact and the case for intervention. London: London School of Economics & Political Science; 2008.
Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson B, Godfrey C, et al. Methods for assessing the cost-effectiveness of public health interventions: key challenges and recommendations. Health Policy. 2009;93(2–3):85–92.
Hallam A, Trieman N. The cost effectiveness of specialised facilities for service users with persistent challenging behaviours. Health Soc Care Community. 2001;9(6):429–35.
Slothuus U. An evaluation of selected literature on the measurement of costs in health economic evaluations. Odense: Syddansk Universitets Trykkeri. (Health economics papers, 3); 2000.
Gray A, Clarke P, Wolstenholme J, Worsworth S. Applied methods of cost-effectiveness analysis in health care. 1st ed. Oxford: Oxford University Press; 2011.
Byford S, Leese M, Knapp M, Seivewright H, Cameron S, Jones V, et al. Comparison of alternative methods of collection of service use data for the economic evaluation of health care interventions. Health Econ. 2007;16(5):531–6.
Chisholm D, Knapp MKH, Amaddeo F, Gaite L, Winjgaarden B. Client socio-demographic service receipt inventory European version: development of one intrument for international research. Br J Psychiatry. 2000;177(39):s28–33.
Riewpaiboon A, Malaroje S, Kongsawatt S. Effect of costing methods on unit cost of hospital medical services. Tropical Med Int Health. 2007;12(4):554–63.
Oostenbrink JB, Buijs-Van der Woude T, van Agthoven M, Koopmanschap MA, Rutten FF. Unit costs of inpatient hospital days. PharmacoEconomics. 2003;21(4):263–71.
McFarkand B, Smith J, Bigelow D, Mofidi A. Unit of costs of community mental health services. Admin Pol Ment Health. 1995;23(1):27–42.
Curtis L, Burn A. Unit of costs of health & social care 2015. Personal Social Services Research Unit; 2015.
Mullins C, Seal B, Seoane-Vasquez E, Sankaranarayanan J, Asche C, Jayadevappa R, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: medicare, medicaid and other US government payers perspectives: the ISPOR drug cost task force report—part IV. Value Health. 2010;13(1):18–24.
Mansley E, Carroll N, Chen K, Shah N. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspeective: the ISPOR drug cost task force report-part III. Value Health. 2010;13(1):14–7.
South American Institute of Government in Health, Giovanella L, Feo O, Faria M, Tobar K. Health systems in South America: challenges to universality, integrality and equity. Rio de Janeiro: ISAGS; 2012.
Razzouk D, Kayo M, Sousa A, Gregorio G, Cogo-Moreira H, Cardoso AA, et al. The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, Brazil. PLoS One. 2015;10(4):e0124791.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Razzouk, D. (2017). Methods for Measuring and Estimating Costs. In: Razzouk, D. (eds) Mental Health Economics. Springer, Cham. https://doi.org/10.1007/978-3-319-55266-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-55266-8_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55265-1
Online ISBN: 978-3-319-55266-8
eBook Packages: MedicineMedicine (R0)